JAK2V617F allele burden is reduced by busulfan therapy: A new observation using an old drug

Haematologica

Volumn 98, Issue 11, 2013, Pages

  Kuriakose, Emil T ^a   Gjoni, Stefani ^a   Wang, Y Lynn ^a   Baumann, Ruth ^a   Jones, Amy V ^b   Cross, Nicholas C P ^c   Silver, Richard T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

AML MDS; Busulfan; Polycythemia vera; PV

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; DASATINIB; HYDROXYUREA; IMATINIB; JANUS KINASE 2; PHOSPHORUS 32; PIPOBROMAN; JAK2 PROTEIN, HUMAN; MYELOABLATIVE AGENT;

AGED; ALLELE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LETTER; LEUKEMIA; LEUKEMOGENESIS; LOW DRUG DOSE; MALE; PHLEBOTOMY; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PYROSEQUENCING; QUALITY OF LIFE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOXICITY TESTING; AML/MDS; GENETICS; PV; VERY ELDERLY;

AML/MDS; BUSULFAN; POLYCYTHEMIA VERA; PV;

AGED; AGED, 80 AND OVER; ALLELES; BUSULFAN; FEMALE; HUMANS; JANUS KINASE 2; MALE; MYELOABLATIVE AGONISTS; POLYCYTHEMIA VERA;

EID: 84887008308     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.087742     Document Type: Letter

References (17)

1. Brodsky I. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). Am J Clin Oncol. 1998; 21: 105-6.
2. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E. O. R. T. C.) Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Br J Cancer. 1981; 44(1): 75-80.
3. Wang YL, Vandris K, Jones A, Cross NC, Christos P, Adriano F, et al. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia. 2008; 22(6): 1289.
4. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009; 113: 4829-33.
5. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008; 112(8): 3065-72.
6. Quintas-Cardama A, Kantarjian H, Manshouri T, Manshouri T, Luthra R, Estrov Z, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thromobocythemia and polycythemia vera. J Clin Oncol. 2009; 27(32): 5418-24.
7. Spanoudakis E, Bazdiara I, Kotsianidis I, Margaritis D, Goutzouvelidis A, Christoforidou A, et al. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. Ann Hematol. 2009; 88(7): 629-32.
8. Kuriakose E, Vandris K, Wang YL, Chow W, Jones A, Christos P, et al. Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica. 2012; 97(4): 538-42.
9. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011; 118(7): 1723-35.
10. Brodsky I. The use of ferrokinetics in the evaluation of busulphan therapy in polycythaemia vera. Br J Haematol. 1964; 10: 291-8.
11. Brodsky I. Busulphan treatment of polycythemia vera. Br J Haematol. 1982; 52: 1-6.
12. Dunn CDR. The chemical and biological properties of busulphan ('Myleran'). Expt Hematol. 1974; 2: 101-7.
13. Berk PD, Goldman JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986; 23(2): 132-43.
14. Hehlmann R, Hempel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993; 82: 398-407.
15. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994; 84: 4064-77.
16. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005; 105: 2664-70.
17. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000; 110: 577-83.